Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
DARVON COMPOUND is a fixed-dose combination oral capsule containing propoxyphene hydrochloride (a weak opioid), aspirin (NSAID), and caffeine, approved in 1957 for pain management. The combination leverages synergistic analgesic effects: propoxyphene provides opioid-based pain relief while aspirin adds anti-inflammatory benefit and caffeine enhances alertness. It was historically used for mild-to-moderate pain across multiple indications.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); shrinking team focus typical of legacy analgesic portfolios.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on DARVON COMPOUND offers limited career advancement; the product is in decline with no linked job openings and minimal commercial momentum. Roles are primarily defensive and focused on managing existing market share, compliance, and transition planning rather than growth or innovation.
Worked on DARVON COMPOUND at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.